Autologous bone marrow transplantation for children with AML in first remission

Bone Marrow Transplantation

Volumn 40, Issue 4, 2007, Pages 313-318

  Neudorf, S ^a   Sanders, J ^b   Kobrinsky, N ^c   Alonzo, T A ^d   Buxton, A ^e   Buckley, J D ^d   Howells, W ^d   Gold, S ^f   Barnard, D R ^g   DeSwarte, J ^h   Kalousek, D ⁱ   Lange, B J ^j   Woods, W G ^k  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^b USA   (United States)

^c MeritCare Roger Maris Cancer Center   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e CHILDREN S ONCOLOGY GROUP   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g Izaak Walton Killam Hospital for Children   (Canada)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ BC CHILDREN S HOSPITAL   (Canada)

^j CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^k EMORY UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROPEROXYCYCLOPHOSPHAMIDE; BUSULFAN; CYCLOPHOSPHAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW CELL; BONE MARROW PURGING; CHILD; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DONOR; ENGRAFTMENT; FEMALE; GRAFT RECIPIENT; HLA MATCHING; HUMAN; INFANT; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; THROMBOCYTE;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GRAFT SURVIVAL; HUMANS; INFANT; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; PROSPECTIVE STUDIES; REMISSION INDUCTION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 34547670938     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705680     Document Type: Article

References (26)

1. Woods WG, Kobrinsky N, Buckley JD, Lee JW, Sanders J, Neudorf S et al. Timed-sequential induc6on therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood 1996; 87: 4979-4989.
2. Woods WG, Neudorf S, Gold S, Sanders J, Buckley JD, Barnard DR et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001; 97: 56-62.
3. Ravindranath Y, Yeager AM, Chang MN, Steuber CP, Krischer J, Graham-Pole J et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood. N Engl J Med 1996; 334: 1428-1434.
4. Amadori S, Testi AM, Arico M, Comelli A, Giuliano M, Madon E et al. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. J Clin Oncol 1993; 11: 1046-1054.
5. Bonetti F, Zecca M, Pession A, Messina C, Montagna D, Lanino E et al. Total-body irradiation and melphalan is a safe and effective conditioning regimen for autologous bone marrow transplantation in children with acute myeloid leukemia in first remission. J Clin Oncol 1999; 17: 3729-3733.
6. Vignetti M, Rondelli R, Locatelli F, Lanino E, Miniero R, Rossetti F et al. Autologous bone marrow transplantation in children with acute myeloblastic leukemia: Report from the Italian National Pediatric Registry (AIEOP-BMT). Bone Marrow Transplant 1996; 18 (Suppl 2): 59-62.
7. Tiedemann K, Waters KD, Tauro GP, Tucker D, Ekert H. Results of intensive therapy in childhood acute myeloid leukemia, incorporating high-dose melphalan and autologous bone marrow transplantation in first complete remission. Blood 1993; 82: 3730-3738.
8. Ball ED, Wilson J, Phelps V, Neudorf S. Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: Results of phase II studies with long-term follow-up. Bone Marrow Transplant 2000; 25: 823-829.
9. Yeager AM, Kaizer H, Santos GW, Saral R, Colvin OM, Stuart RK et al. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4 hydroperoxycyclophosphamide. N Engl J Med 1986; 315: 141-147.
10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 475-481.
11. Kalbfleish JD, Prentice RL. The Statistical Analysis of Failure Time Data, 2nd edn. John Wiley & Sons: Hoboken, NJ, USA, 2002.
12. Sposto R. Cure model analysis in cancer: An application to data from the Children's Cancer Group. Stat Med 2002; 21: 293-312.
13. Hassan M, Ljungman P, Bohne P, Ringden O, Syrckova Z, Bekassy A et al. Busulfan bioavailability. Blood 1994; 84: 2144-2150.
14. Vassal G, Fischer A, Challine D, Boland I, Ledheist F, Lemerle S et al. Busulfan disposition below the age of three: Alteration in children with lysosomal storage disease. Blood 1993; 82: 1030-1034.
15. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI et al. Marrow transplantation for chronic myeloid leukemia the influence of plasma busulfan levels on the outcome of, transplantation. Blood 19971, 89: 3055-3060.
16. Blaise D, Maraninchi D, Michallet M, Reiffers J, Jouet JP, Milpied N et al. Long-term follow-up of a randomized trial companing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission. Blood 2001; 97: 3669-3671.
17. Michel G, Gluckman E, Esperou-Bourdeau H, Reiffers J, Pico JL, Bordigoni P et al. Allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: Impact of conditioning regimen without total-body irradiation - a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 1994; 12 1217-1222.
18. Ringden O, Ruutu T, Remberger M, Nikoskelainen J, Volin L, Vindelov L et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: A report from the Nordic Bone Marrow Transplantation Group. Blood 1994, 83: 2723-2730.
19. Socié G, Clift R, Blaise D, Devergie A. Ringden O, Martin PJ et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: Long-term follow-up of 4 randomized studies. Blood 2001; 98: 3569-3574.
20. Woolfrey A, Gooley T, Sievers E, Milner LA, Andrews RG, Walters M et al. Bone marrow transplantation for children less than 2 years of age with acute myelogenous leukemia or myelodysplastic syndrome. Blood 1998; 92: 3546-3556.
21. Brenner MK, Rill DR, Moen RC, Krance RA, Mirro Jr J, Anderson WF et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-89.
22. Gorin NC, Aegerter P, Auvert B, Meloni G, Goldstone AH, Burnett A et al. Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: A European survey of the role of marrow purging. Blood 1990; 75: 1606-1614.
23. Cortes JE, Kantarjian HM, O'Brien S, Giles F, Keating MJ, Freireich EJ et al. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer 1999; 85: 1506-1513.
24. Sievers EL, Lange BJ, Sondel PM, Krailo MD, Gan J, Tjoa T et al. Children's cancer group trials of interleukin-2 therapy to prevent relapse of acute myelogenous leukemia. Cancer J Sci Am 2000; 6 (Suppl 1): S39-S44.
25. Steins M, Padró T, Bieker R, Ruiz S, Kropff M, Kienast J et al. Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 2002; 99: 834-839.
26. Sievers EL, Larson RA, Stadtmauer EA, Estey E, Lowenberg B, Dombret H et al., Mylotarg Study Group. Efficacy and safety of gemtuzamab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol 2001; 19: 3244-3254.